Eli Lilly and Co LLY
News
Eli Lilly on Track for Record High Close — Data Talk
Eli Lilly Reports More than 50% Remission Rate in Crohn's Treatment Trial
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Eli Lilly Ethics/Compliance Chief Alonzo Weems to Retire
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug
Lilly Declares Second-Quarter 2024 Dividend
Amgen 'very encouraged' by data from weight-loss-drug trial, as stock jumps
Trending: Eli Lilly Reports Strong Sales of Weight-Loss, Diabetes Drugs
Eli Lilly's stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro, Zepbound
Eli Lilly Up Nearly 7%, on Pace for Largest Percent Increase Since August 2023 — Data Talk
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Nvidia is the No. 1 S&P 500 growth stock in -2-
Nvidia is the No. 1 S&P 500 growth stock in this screen. See which other companies joined or left the list.
Eli Lilly says weight-loss drug Zepbound proved effective as a treatment for sleep apnea
Trending: Eli Lilly Weight-Loss Drug Works on Sleep Apnea
Studies Show Eli Lilly Weight-Loss Drug Helps With Sleep Apnea